Susan Goelz

Biogen (United States) — United States

Medicine · Health Sciences

38h-index9.5kcitations89works2.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Polyomavirus and related diseases(25), Multiple Sclerosis Research Studies(21), Monoclonal and Polyclonal Antibodies Research(14), Full-Duplex Wireless Communications(12), Cytokine Signaling Pathways and Interactions(11)

Publications89 total

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and <scp>CSF</scp> Cell Composition
Annals of Clinical and Translational Neurology·2025Open Access
Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy
Cell Reports Medicine·2024· 7 citedOpen Access
Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum
Multiple Sclerosis and Related Disorders·2024Open Access
Comprehensive proteomic analysis of JC polyomavirus-infected human astrocytes and their extracellular vesicles
Microbiology Spectrum·2023· 8 citedOpen Access
High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4+ T cell arrest on the inflamed BBB under flow in vitro
Journal of Neuroinflammation·2023· 16 citedOpen Access
Comprehensive proteomic analysis of JC polyomavirus-infected human astrocytes and their excreted vesicles
2023Open Access
Can Natalizumab be Safely Used After Ocrelizumab in Treating Multiple Sclerosis?
International Journal of Neuroscience and Research·2023· 1 citedOpen Access
A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis
Science Translational Medicine·2022· 78 citedOpen Access
Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair
Multiple Sclerosis and Related Disorders·2022· 13 cited
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
Journal of Personalized Medicine·2021· 5 citedOpen Access
Is the gut a relevant reservoir for persistent jcpyv infection
Kölner Universitäts PublikationsServer (Universität zu Köln)·2020
Mary B. Kennedy
Society for Neuroscience eBooks·2020Open Access
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
Multiple Sclerosis and Related Disorders·2019· 51 cited
A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity
Nature Immunology·2017· 160 citedOpen Access
Pilomotor function is impaired in patients with Parkinson's disease: A study of the adrenergic axon-reflex response and autonomic functions
Parkinsonism & Related Disorders·2016· 16 cited
JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection
PLoS ONE·2016· 21 citedOpen Access
Brain Endothelial- and Epithelial-Specific Interferon Receptor Chain 1 Drives Virus-Induced Sickness Behavior and Cognitive Impairment
Immunity·2016· 182 citedOpen Access
Distribution of protein I in mammalian brain as determined by a detergent-based radioimmunoassay (protein kinase/protein phosphorylation/synapse/nerve terminals)
2016
Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis
PLoS ONE·2013· 37 citedOpen Access
<scp>l</scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Neurology·2013· 141 cited
page 1 of 5Next →

Frequent Co-authors

Ralf Gold(5), G Chi-Rosso(5), Roy R. Lobb(5), Alfred Sandrock(4), Leonid Gorelik(4), Heinz Wiendl(4), Christopher D. Benjamin(4), Meena Subramanyam(3), Tatiana Plavina(3), Catherine Hession(3), Andrew Chan(3), Ralf A. Linker(2), Bert Vogelstein(2), Stanley R. Hamilton(2), Sarah A. Bixler(2), Kenneth J. Simon(2), Michael David(2), Andrew C. Larner(2), Richard Tizard(2), Laura Runkel(2)